id: NEW:glp1_receptor_agonist_treatment_access_to_substance_use_disorder_any
name: GLP-1 Receptor Agonist Treatment Access â†’ Substance Use Disorder (Any)
from_node:
  node_id: NEW:glp1_receptor_agonist_treatment_access
  node_name: GLP-1 Receptor Agonist Treatment Access
to_node:
  node_id: substance_use_disorder_any
  node_name: Substance Use Disorder (Any)
direction: negative
category: healthcare_access
mechanism_pathway:
- 'Step 1: GLP-1 receptor agonists administered systemically cross blood-brain barrier to access central
  receptors'
- 'Step 2: Brain GLP-1 receptor activation modulates mesolimbic reward circuitry'
- 'Step 3: Reduced reward salience and craving for substances of abuse'
- 'Step 4: Decreased pathological substance consumption across multiple substance classes'
evidence:
  quality_rating: B
  n_studies: 3
  primary_citation: Jingchuan Guo et al. 2025. "GLP-1 Receptor Agonists and Research to Treat Overeating
    and Substance Use Disorders.." https://doi.org/10.1523/JNEUROSCI.1375-25.2025
  supporting_citations:
  - Basic science research referenced in abstract
  - Human clinical data referenced in abstract
  - Real-world observations referenced in abstract
  doi: 10.1523/JNEUROSCI.1375-25.2025
  citation_verified: true
last_updated: '2025-12-06'
version: '2.0'
description: GLP-1 receptor agonists demonstrate potential for treating multiple substance use disorders
  through shared neurobiological mechanisms involving central nervous system reward pathway modulation.
moderators:
- name: substance_type
  direction: strengthens
  strength: moderate
  description: Evidence suggests efficacy across multiple substance classes including alcohol and other
    substances
structural_competency:
  equity_implications: The identification of a common biological mechanism across substance use disorders
    challenges stigmatizing narratives that frame addiction as moral failing. Structural factors determining
    access to these treatments (insurance coverage, prescriber availability, drug costs) will shape who
    benefits from this therapeutic approach. Disparities in diabetes and obesity treatment access suggest
    similar inequities may emerge for SUD applications.
llm_metadata:
  extracted_by: claude-opus-4-5-20251101
  extraction_date: '2025-12-06T21:12:37.178474'
  extraction_confidence: medium
  prompt_version: 2.1-canonical-validated
